Robert W. Baird analyst Catherine Schulte maintained a Buy rating on NanoString Tech (NASDAQ: NSTG) today and set a price target of $18. The company’s shares closed yesterday at $16.39, close to its 52-week high of $16.80.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 31.6% and a 82.9% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Bio-Techne Corporation, Oxford Immunotec, and Exact Sciences.
Currently, the analyst consensus on NanoString Tech is a Moderate Buy with an average price target of $16.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.80 and a one-year low of $5.87. Currently, NanoString Tech has an average volume of 261.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway.
